BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 16, 2016
View Archived Issues
Homology Medicines gains rights to AAV technology from Caltech
Read More
First patient dosed in phase Ib study of Xencor's XmAB-7195
Read More
Eisai launches AiM Institute
Read More
Promising immunotherapy for type 1 diabetes tested in phase I study
Read More
AcelRx Pharmaceuticals's ARX-04 well tolerated in phase III trial
Read More
DSMB recommends continuation of Celsion's phase Ib OVATION study
Read More
Long QT syndrome patients with triple gene mutations have more severe symptoms
Read More
FDA approves Aralez Pharmaceuticals' Yosprala
Read More
Phase III results reported for ertugliflozin in addition to metformin and sitagliptin for diabetes
Read More
Pfizer initiates phase IIa trial of PF-06480605 in moderate to severe ulcerative colitis
Read More
Nitto Denko patents carboxylesterase inhibitors
Read More
Inotrem completes phase I study of Motrem
Read More
Dosing begins in phase I study of Calithera Biosciences' CB-1158
Read More
GSK begins dosing patients in phase I study of PRMT5 inhibitor
Read More
Liraglutide may exert epigenetic effect in T2DM patients
Read More
National Cancer Center of Japan and Ono sign comprehensive research collaboration agreement
Read More
Novartis explores anticancer effects of inhibiting the COP9 signalosome
Read More
Astellas Pharma forms partnership with Courtagen Life Sciences
Read More
FDA grants QIDP status to Viamet Pharmaceuticals' VT-1598
Read More
Trek Therapeutics reports results from phase IIa study of triple-drug combo for HCV
Read More
Gene Techno Science initiates phase III trial of darbepoetin alfa biosimilar in Japan
Read More
New biomarker signature predicts microvascular outcomes in dysglycemia
Read More
EMA's CHMP recommends conditional approval of Lilly's olaratumab
Read More